Загрузка...
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
BACKGROUND: Response criteria developed when cytotoxic chemotherapy was the predominant therapeutic modality to treat patients with cancer, do not capture the full spectrum of tumor response patterns observed with anti-PD-1/PD-L1 antibody treatment. iRECIST was developed to capture both typical and...
Сохранить в:
| Опубликовано в: : | J Immunother Cancer |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057528/ https://ncbi.nlm.nih.gov/pubmed/32107275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000146 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|